Soleno Therapeutics, Inc. $SLNO Shares Bought by Swiss National Bank

Swiss National Bank increased its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 9.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 50,100 shares of the company’s stock after purchasing an additional 4,200 shares during the quarter. Swiss National Bank owned 0.10% of Soleno Therapeutics worth $3,580,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Janus Henderson Group PLC raised its holdings in Soleno Therapeutics by 27.1% in the 4th quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company’s stock worth $233,130,000 after purchasing an additional 1,107,166 shares during the period. Nantahala Capital Management LLC raised its holdings in Soleno Therapeutics by 20.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company’s stock worth $176,607,000 after purchasing an additional 658,518 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Soleno Therapeutics by 24.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company’s stock worth $73,301,000 after purchasing an additional 321,223 shares during the period. Westfield Capital Management Co. LP raised its holdings in Soleno Therapeutics by 37.4% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,211,245 shares of the company’s stock worth $86,543,000 after purchasing an additional 329,785 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Soleno Therapeutics by 47.2% in the 4th quarter. Vestal Point Capital LP now owns 1,060,000 shares of the company’s stock worth $47,647,000 after purchasing an additional 340,000 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Price Performance

NASDAQ:SLNO opened at $68.94 on Thursday. Soleno Therapeutics, Inc. has a 12 month low of $41.50 and a 12 month high of $90.32. The stock has a 50 day moving average of $82.37 and a two-hundred day moving average of $69.55. The company has a current ratio of 15.13, a quick ratio of 15.01 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.66 billion, a P/E ratio of -16.65 and a beta of -2.56.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.44. The company had revenue of $32.66 million during the quarter, compared to analysts’ expectations of $3.91 million. On average, analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SLNO. Oppenheimer upped their price target on Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Guggenheim boosted their price objective on Soleno Therapeutics from $97.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Cowen reiterated a “buy” rating on shares of Soleno Therapeutics in a research note on Thursday, August 7th. Robert W. Baird set a $121.00 price objective on Soleno Therapeutics and gave the stock an “outperform” rating in a research note on Friday, July 11th. Finally, Piper Sandler boosted their price objective on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an “overweight” rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $115.09.

Insider Activity

In other news, insider Patricia C. Hirano sold 3,830 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total value of $316,970.80. Following the completion of the sale, the insider directly owned 13,206 shares in the company, valued at $1,092,928.56. This represents a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.40% of the stock is owned by company insiders.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.